

1 **Title:** Plasma proteomic signatures of adiposity are associated with cardiovascular risk factors and
2 type 2 diabetes risk in a multi-ethnic Asian population.

3 **Short running title:** Proteomics of adiposity

4 **Authors:** Charlie G.Y. Lim¹, Bige Ozkan^{2,3}, Yujian Liang¹, Jiali Yao¹, Nang Ei Ei Khaing¹, Mary R.
5 Rooney², Chiadi E. Ndumele^{2,3}, E Shyong Tai^{1,4}, Josef Coresh², Xueling Sim^{1*}, and Rob M. van
6 Dam^{1,5,*}

7 **Authors affiliations:**

8 ¹ Saw Swee Hock School of Public Health, National University of Singapore and National University
9 Health System, 12 Science Drive 2, Singapore 117549 (C.G.Y.L., Y.L., J.Y., N.E.E.K., E.S.T., X.S.,
10 R.M.vD.)

11 ² Department of Epidemiology and the Welch Center for Prevention, Epidemiology, and Clinical
12 Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA (B.O.,
13 M.R.R., C.E.N., J.C.)

14 ³ Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Johns
15 Hopkins University School of Medicine, Baltimore, Maryland, USA (B.O., C.E.N.)

16 ⁴ Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, 10
17 Medical Dr, Singapore 117597 (E.S.T.)

18 ⁵ Departments of Exercise and Nutrition Sciences and Epidemiology, Milken Institute School of
19 Public Health, The George Washington University, 950 New Hampshire Ave, NW, Washington, DC
20 20052 (R.M.vD.)

21 *These authors jointly supervised this work

22

23 **Corresponding Authors:**

24 Xueling Sim
25 Saw Swee Hock School of Public Health, National University of Singapore
26 12 Science Drive 2, Singapore 117549
27 Tel: +65 6601 5096
28 E-mail: ephx@nus.edu.sg

29
30 Rob M. van Dam
31 Department of Exercise and Nutrition Sciences, Milken Institute School of Public Health, The George
32 Washington University
33 950 New Hampshire Ave NW #2, Washington DC 20052
34 Tel: +1-202-994-9412
35 E-mail: rvandam@gwu.edu

36

37 **Abstract**

38 The molecular mechanisms connecting obesity and cardiometabolic diseases are not fully
39 understood. We evaluated the associations between body mass index (BMI), waist
40 circumference (WC), and ~5,000 plasma proteins in the Singapore Multi-Ethnic Cohort
41 (MEC1). Among 410 BMI-associated and 385 WC-associated proteins, we identified protein
42 signatures of BMI and WC and validated them in an independent dataset across two
43 timepoints and externally in the Atherosclerosis Risk in Communities (ARIC) study. The
44 BMI- and WC-protein signatures were highly correlated with total and visceral body fat,
45 respectively. Furthermore, the protein signatures were significantly associated with
46 cardiometabolic risk factors and were able to differentiate between metabolically healthy and
47 unhealthy obesity. In prospective analyses, the protein signatures were strongly associated
48 with type 2 diabetes risk in MEC1 (odds ratio per SD increment in WC-protein signature =
49 2.84, 95% CI 2.47 to 3.25) and ARIC (hazard ratio = 1.97, 95% CI 1.87 to 2.07). Pathways
50 related to cell signaling, systemic inflammation, and glucose and fat metabolism were
51 overrepresented in the BMI- and WC-protein signatures. Our protein signatures have
52 potential uses for the monitoring of metabolically unhealthy obesity.

53 **Article Highlights**

- 54 • We evaluated the associations between ~5000 plasma proteins and BMI and WC in a
55 multi-ethnic Asian population.
- 56 • We identified 410 proteins associated with BMI and 385 proteins associated with WC and
57 derived protein signatures of BMI and WC, which we validated externally in a US cohort.
- 58 • Both the BMI- and WC-protein signatures were strongly associated with cardiometabolic
59 risk factors and the risk of type 2 diabetes and were enriched in pathways relating to cell
60 signaling, systemic inflammation, and glucose and fat metabolism.
- 61 • Our protein signatures have potential uses for monitoring metabolically unhealthy
62 obesity.

63 Obesity is a metabolic disorder resulting from a complex interplay between genetic,
64 psychosocial, and environmental factors (1). Although obesity is a major risk factor for
65 metabolic diseases such as type 2 diabetes and cardiovascular diseases (CVDs) (2), the
66 biological mechanisms connecting obesity and these metabolic diseases are not fully
67 understood.

68 Proteins are important biomarkers for identifying biological pathways linking genetic and
69 environmental exposures to disease risk (3). Recent studies in European populations have
70 identified proteins associated with body mass index (BMI) (4–6), highlighting pathways
71 involved in lipid metabolism and inflammations that may contribute to obesity-related
72 diseases (5). However, these studies were based on platforms that covered a limited number
73 of proteins (~1100-3600 proteins), used BMI as the only measure of adiposity, and included
74 participants of predominantly European ancestry. The latter may be particularly important
75 given the well-recognized differences in the association of BMI with type 2 diabetes in
76 populations of Asian compared to European ancestry (7). Finally, previous studies did not
77 examine whether obesity-related proteins are associated with cardiometabolic health.

78 We evaluated the associations between ~5000 plasma proteins, and BMI and waist
79 circumference (WC) in a multi-ethnic Asian population comprising adults of Chinese, Malay,
80 and Indian ethnicity. Using machine learning techniques, we developed protein signatures of
81 BMI and WC and evaluated their associations with total and visceral body fat, CVD risk
82 factors, and the incidence of type 2 diabetes.

83 **Research Design and Methods**

84 **Study design**

85 An overview of this study is shown in **Figure 1**. Participants in this study were sampled from
86 the Singapore Multi-Ethnic Cohort Phase 1 (MEC1) (8). The MEC1 is a population-based

87 cohort comprising 14,465 male and female adults recruited between 2004 and 2010.
88 Oversampling of ethnic minorities (Malay and Indians) was done to achieve a good
89 representation of three major Asian ethnic groups in Singapore—Chinese, Malay, and Indian.
90 Between 2011 to 2016 (mean follow-up of 6.4 years), 6,112 participants agreed to a follow-
91 up visit. Participants completed a standardized interviewer-administered questionnaire on
92 socio-demographic characteristics, lifestyle, and medical history for both the baseline and
93 follow-up study. Height was measured without shoes on a portable stadiometer, while weight
94 was measured on a digital scale. WC was measured by trained research staff using stretch-
95 resistant tape at the mid-point between the last rib and iliac crest. Blood was drawn for
96 biomarker measurements and biobanking at -80°C .

97 At follow-up, a subset of Chinese participants underwent Dual-Energy X-ray Absorptiometry
98 (DXA) and Computed Tomography (CT) scan (9). For the DXA measurements, total body fat
99 mass, trunk fat mass, android fat mass, and lean body mass were assessed using a medium-
100 speed total body acquisition mode (Discovery Wi, Hologic, Bedford, MA, and software
101 Hologic Apex 3.01). For the CT scan, images at the inter-vertebral space L2/L3 level were
102 identified by a single observer (sliceOmatic version 5.0, Tomovision, Magog, Canada).
103 Visceral adipose tissue (VAT) at the L2/L3 level was most strongly correlated with
104 cardiovascular risk factors in Chinese adults (10). The images were analyzed by two
105 independent readers using a workstation (eFilm Workstation version 4.0, Hartland, USA),
106 and readings for VAT area and subcutaneous adipose tissue (SAT) area were averaged. The
107 average inter-observer coefficient of variation was 2.34% for SAT and 3.22% for VAT.

108 Selected MEC1 participants were profiled on the SomaScan proteomic assay. First, a random
109 sample of 720 participants with equal numbers in each sex and ethnic group were included as
110 the Population Set. The second set included 759 incident type 2 diabetes cases and 1,484
111 matched controls as the type 2 diabetes case-control (T2DCC) set. Incident type 2 diabetes

112 cases were ascertained through record linkage with a national healthcare database, self-
113 reported physician-diagnosis of diabetes at follow-up, or having a fasting blood glucose \geq
114 7mmol/L or random blood glucose \geq 11mmol/L or A1C \geq 6.5% at follow-up (11). Controls
115 were selected using risk-set sampling and were matched 1:2 according to age (\pm 5 years), sex,
116 ethnicity, and date of blood collection (\pm 2 years). Of 4,897 samples from 2,981 participants
117 sent to SomaLogic, 609 samples were not measured due to shipment issues. We excluded
118 samples that failed SomaLogic quality control, duplicate samples, participants from ethnic
119 groups other than Chinese, Malay, or Indian, participants with a history of heart disease at
120 baseline, and those with missing anthropometric data (**Supplementary Table 1**). The final
121 number of participants for analyses was 631 from the Population Set and 616 cases and 1,200
122 controls from the T2DCC Set. Written consent was obtained from all participants, and this
123 study was approved by the National University of Singapore Institutional Review Board
124 (reference code: N-18-059).

125 We externally replicated our findings in the Atherosclerosis Risk in Communities (ARIC)
126 Study, a population-based cohort study in the USA. Participants were male and female adults
127 and white and African American. Details on the ARIC study have been reported elsewhere
128 (12). After the exclusion of participants with diabetes (defined based on self-report diagnosis,
129 medication use, fasting glucose \geq 7mmol/L, or HbA1c \geq 6.5%) or heart diseases at baseline,
130 we included a total of 8,428 ARIC participants with proteomic data measured on the
131 SomaScan V4 platform during Visit 2 (1990-1992) in our analyses. Over a median follow-up
132 duration of 19.4 years, 1,800 diabetes incident cases were ascertained based on self-reported
133 diagnosis by a healthcare provider or glucose-lowering medication use reported by
134 participants during annual follow-up telephone calls or clinic visits.

135 **Proteomic assay**

136 Relative protein abundances were measured in plasma samples using an aptamer-based
137 technology (SomaScan V4 assay) by SomaLogic, Inc. (Boulder, Colorado, US). Details of
138 the SomaScan assay (13,14) and the reproducibility and specificity of the SomaScan assay
139 have been reported previously (15–19).

140 For this study, relative fluorescence units (RFU) for 5,284 SOMAmers were obtained. After
141 excluding 298 SOMAmers that targeted non-human proteins, 7 deprecated SOMAmers and 1
142 SOMAmer that targeted a protein whose annotation was withdrawn by the National Center
143 for Biotechnology Information (20), 4,978 SOMAmers targeting 4,775 human proteins
144 remained.

145 **Statistical analysis**

146 All data analyses were based on \log_2 transformed RFU and winsorized at ± 5 standard
147 deviations to reduce the impact of extreme outliers. All P-values reported are from two-sided
148 tests. R version 4.2.0 was used.

149 **Discovery and internal validation of protein signatures of BMI and WC**

150 Using the Population Set at baseline as the discovery, we evaluated ethnic-specific
151 associations between protein levels and BMI and WC adjusted for age and sex. The ethnic-
152 specific results were pooled using fixed-effects inverse-variance meta-analysis.

153 We defined associated proteins as those that were (i) significantly associated with the trait of
154 interest (BMI or WC) at the Bonferroni corrected threshold ($P < 1.00 \times 10^{-05}$), (ii) had the
155 same direction of association across three ethnic groups, and (iii) had no evidence of
156 statistical heterogeneity using the Cochran Q test ($P_{\text{het}} > 1.00 \times 10^{-05}$). For proteins targeted by
157 multiple SOMAmers, the SOMAmer with the smallest P-value was selected. Using the
158 associated proteins, we performed 100 replicates of 10-fold cross-validation elastic net
159 regression analysis (21). The elastic net regression is a regularized regression method that

160 enables automatic variable selection and variance reduction (21). The BMI-protein and WC-
161 protein signatures were calculated as the weighted sum of the concentration of the selected
162 proteins, with the weights being the beta coefficients from the elastic net regression model.
163 Using the T2DCC Set as the validation, we examined cross-sectional correlations between
164 the protein signatures and BMI and WC at baseline and follow-up and the correlations
165 between changes in the protein signatures and changes in BMI and WC over a ~6-year
166 period. On a subset of Chinese participants with DXA measurements (total body fat mass,
167 trunk fat mass, android fat mass, and percentage of lean mass) ($n = 207$) and VAT and SAT
168 measurements ($n = 151$), we computed the Pearson correlation coefficients.

169 **Association between protein signatures and CVD risk factors**

170 We evaluated associations between the protein signatures and systolic blood pressure, HDL
171 cholesterol, LDL cholesterol, triglycerides, fasting glucose, and A1C among participants in
172 the T2DCC Set. We used linear regression models adjusted for age, sex, and ethnicity and
173 standardized all predictor variables to facilitate the comparison of effect sizes. The difference
174 in standardized beta coefficients was evaluated using the Z-test. Participants on anti-
175 hypertensive medication were excluded from analyses involving systolic blood pressure, and
176 participants on lipid-lowering medications were excluded from analyses involving blood
177 lipids.

178 We evaluated our protein signatures' ability to differentiate between metabolically healthy
179 and metabolically unhealthy obesity (22) among overweight or obese individuals ($BMI \geq$
180 23.0 kg/m^2) in the T2DCC set at baseline. We defined metabolically unhealthy as having two
181 or more of the four metabolic abnormalities: (i) hypertension defined as having a systolic
182 blood pressure $\geq 130 \text{ mmHg}$ or diastolic blood pressure $\geq 85 \text{ mmHg}$; (ii) elevated fasting
183 plasma glucose, defined as $\geq 5.6 \text{ mmol/L}$, (iii) elevated triglycerides defined as ≥ 1.7

184 mmol/L, and (iv) reduced HDL cholesterol defined as < 1.0 mmol/L for males and < 1.3
185 mmol/L for females. We used logistic regression models with metabolic health status as the
186 outcome and standardized protein signatures as predictors, adjusted for age, sex, ethnicity,
187 and BMI.

188 **Association between protein signatures and type 2 diabetes incidence**

189 We applied the BMI and WC protein signatures on the T2DCC Set to examine the
190 association with type 2 diabetes incidence using logistic regression models adjusted for age,
191 sex, and ethnicity. Variables were standardized to facilitate comparison with BMI and WC.

192 **External validation of protein signatures in the ARIC study**

193 Using the ARIC study, we first evaluated the associations between anthropometric
194 measurements and each protein in the BMI- and WC-protein signatures, adjusted for age, sex,
195 race, and study center. We consider our adiposity-protein associations replicated if it was
196 statistically significant at the Bonferroni threshold and directionally consistent with the ARIC
197 study. Next, we computed the BMI- and WC-protein signature for each ARIC participant
198 using the weights identified in MEC1 and assessed their correlations with BMI and WC.
199 Finally, we evaluated associations between protein signatures and type 2 diabetes incidence
200 using the Cox proportional hazards model, adjusted for age, sex, race, and study center.

201 **Functional annotation and pathway enrichment analysis**

202 We performed functional annotation of the proteins using the UniProt Knowledgebase (23).
203 We also queried the Gene Ontology (GO) (24), Kyoto Encyclopedia of Genes and Genomes
204 (KEGG) (25), and Reactome (26) databases using the gprofiler2 R package version 0.2.1 (27)
205 to identify functional annotations and pathways that are significantly overexpressed in the
206 sets of proteins in the BMI- and WC-protein signatures using the hypergeometric test, with

207 all proteins measured by the SomaScan V4 as the custom background. Annotations were
208 considered significant at a false discovery rate (FDR) corrected P-value of 0.05 (28).

209 **Data and Resource Availability**

210 Summary statistics for all measured proteins are provided in the Supplementary Tables.
211 Researchers can request data from the Multi-Ethnic Cohort study for scientific purposes
212 through an application process at the listed website (<https://blog.nus.edu.sg/sphs/data-and-samples-request/>). Data will be shared through an institutional data-sharing agreement.

214 **Results**

215 The baseline characteristics of study participants are shown in **Supplementary Table 2**.
216 Participants were 44.0% male and 56.0% female adults with a mean (\pm SD) age of 47.6 (\pm
217 12.0) years. The ethnic distribution was 34.8% Chinese, 32.6% Malay, and 32.7% Indian.

218 **Discovery of the BMI and WC-protein signatures**

219 Using the Population Set as discovery, we evaluated the ethnic-specific associations between
220 plasma protein levels with BMI and WC adjusted for age and sex (**Supplementary Table 3**).
221 In the meta-analysis across ethnic groups, 410 proteins were associated with BMI, and 385
222 proteins were associated with WC, with 359 proteins in common between BMI and WC
223 (**Figure 2**). Across the three ethnic groups, there was no evidence of statistical heterogeneity
224 ($P_{\text{het}} > 1.00 \times 10^{-5}$), and all associations were in the same direction except one protein
225 (complement factor D) for WC, which was excluded from further analyses. All 359
226 overlapping protein-BMI and protein-WC associations were directionally consistent. The top
227 four most strongly associated proteins were the same for BMI and WC, namely leptin (LEP),
228 heart-type fatty acid binding protein (FABP3), insulin-like growth factor-binding protein 1
229 (IGFBP1), and growth hormone receptor (GHR). We performed a look-up of the 410 BMI-
230 associated proteins in three recent proteomics association studies in European adults, the

231 DIOGenes study (n = 494), the INTERVAL study (n = 2,737), and the KORA study (n =
232 4,600) (4–6). Out of the 410 BMI-associated proteins observed in our study, 90 proteins were
233 not measured in these three studies, and 263 (82%) out of the remaining 320 BMI-associated
234 proteins were directionally consistent and significant at the Bonferroni threshold in at least
235 one study (**Supplementary Table 3**).

236 We performed feature selection using elastic net regression analysis based on the BMI- and
237 WC-associated proteins. We identified 124 proteins for the BMI-protein signature and 125
238 proteins for the WC-protein signature, with 60 overlapping proteins in both signatures
239 (**Figure 3** and **Supplementary Table 4**). We compared our protein signatures with the
240 published results of the Fenland Study (15). Of the 124 proteins in our BMI-protein signature,
241 28 (22.3%) were included in the Fenland Study signature for body fat percentage. Similarly,
242 of the 125 proteins in our WC-protein signature, 34 (27.2%) were included in the Fenland
243 Study signature for visceral fat mass (**Supplementary Table 4**).

244 **Internal validation of the protein signatures**

245 We validated the protein signatures identified in the Population Set using the T2DCC Set.
246 The BMI- and WC-protein signatures were strongly correlated with BMI and WC at baseline
247 and follow-up (r ranging from 0.778 to 0.842) (**Table 1** and **Supplementary Figure 1**).
248 Among 814 participants with both baseline and follow-up data, the changes in BMI (r =
249 0.632) and WC (r = 0.438) were directly correlated with changes in the respective protein
250 signatures over the same period (**Supplementary Figure 2**). We also examined the
251 correlations between changes in anthropometric measurements and changes in individual
252 proteins in the respective signatures (**Supplementary Table 5**). The Pearson correlation
253 coefficients ranged from 0.438 (leptin) to -0.469 (adiponectin) for changes in BMI and 0.343

254 (growth hormone receptor) to -0.326 (sex hormone-binding globulin) for changes in WC. All
255 correlation coefficients reported here were significant ($P < 0.001$).

256 In a subset of Chinese participants with DXA and CT measurements, the BMI-protein
257 signature was directly and strongly correlated with total body fat mass ($r = 0.782$) and
258 moderately correlated with SAT ($r = 0.596$) and VAT ($r = 0.676$) (**Table 1**). In comparison
259 with the BMI-protein signature, the WC-protein signature was less strongly correlated with
260 total body fat mass ($r = 0.619$) and SAT ($r = 0.433$) but more strongly correlated with VAT (r
261 $= 0.735$). The scatterplots suggested a direct linear relationship between total body fat mass
262 and the BMI-protein signature ($\beta = 4.98$ kg per SD; $P < 0.001$) and VAT area with the
263 WC-protein signature ($\beta = 48.1$ cm² per SD; $P < 0.001$) (**Figure 4**).

264 **Association between protein signatures and CVD risk factors**

265 In the T2DCC Set, all adiposity-related predictors (BMI, BMI-protein signature, WC, and
266 WC-protein signature) were significantly associated with higher systolic blood pressure, LDL
267 cholesterol, triglycerides, fasting glucose, A1C, and lower HDL cholesterol after adjustment
268 for age, sex, and ethnicity (**Supplementary Table 6**). Protein signatures were significantly
269 more strongly associated with HDL cholesterol, triglycerides, and A1C than anthropometric
270 measurements. Moreover, with the exception of the BMI-protein signature and LDL
271 cholesterol, the associations between the BMI- and WC-protein signatures and CVD risk
272 factors remained statistically significant after further adjustment for BMI or WC
273 (**Supplementary Table 6**).

274 We also evaluated our protein signatures' ability to differentiate between metabolically
275 healthy and unhealthy obesity. Among 1,262 overweight ($\text{BMI} \geq 23$ kg/m²) participants in
276 the T2DCC set, 717 (56.8%) were metabolically unhealthy. After adjusting for age, sex,
277 ethnicity, and BMI, having a higher BMI-protein signature (per SD increment, OR = 2.36,

278 95% CI 1.93 to 2.88) or WC-protein signature (OR = 2.75, 95% CI 2.28 to 3.32) was
279 associated with a higher odds of being metabolically unhealthy. Results were similar when
280 we used the international BMI cut-off of 25.0 kg/m² to define overweight.

281 **Association between protein signatures and type 2 diabetes incidence**

282 In the T2DCC Set, the BMI-protein signature (OR 2.44, 95% CI 2.15 to 2.77) and WC-
283 protein signature (OR 2.84, 95% CI 2.47 to 3.25) were significantly associated with type 2
284 diabetes incidence, with larger effect sizes ($P_{diff} < 0.05$) than BMI (OR 1.91, 95% CI 1.70 to
285 2.14) and WC (OR 2.09, 95% CI 1.86 to 2.36) (**Table 2**). Moreover, the associations between
286 the BMI- and WC-protein signatures and type 2 diabetes remained significant after further
287 adjustment for BMI and WC, respectively.

288 As the effects of adiposity on insulin resistance may be modified by ethnicity (29,30), we
289 conducted further analyses stratified by ethnicity (**Supplementary Table 7**). We found a
290 stronger association between the BMI-protein signature and type 2 diabetes among Malays
291 (OR 2.96, 95% CI 2.33 to 3.77) and Chinese (OR 2.37, 95% CI 1.94 to 2.88) than Indians
292 (OR 1.91, 95% CI 1.55 to 2.35) ($P_{interaction} = 0.019$). Similarly, the WC-protein signature
293 was more strongly associated with type 2 diabetes incidence among Malays (OR 3.59, 95%
294 CI 2.77 to 4.67) and Chinese (OR 2.72, 95% CI 2.20 to 3.37) than Indians (OR 2.21, 95% CI
295 1.76 to 2.77) ($P_{interaction} = 0.028$).

296 **External validation in the ARIC study**

297 Participants in the ARIC study had a mean age of 56.7 (\pm 5.7) years, were mostly female
298 (57%), and were white (81%) or African African (19%) (**Supplementary Table 8**). After
299 Bonferroni adjustment ($P < 0.05/124$ for BMI and $0.05/125$ for WC), 118 (95.2%) of 124
300 proteins in the BMI-protein signature and 124 (99.2%) of 125 proteins in the WC-protein
301 signature were directionally consistent and significantly associated with BMI and WC,

302 respectively (**Supplementary Table 4** and **Supplementary Figure 3**). Concordant with
303 findings in MEC1, the BMI-protein signature was highly correlated with BMI ($r = 0.822$),
304 and the WC-protein signature was highly correlated with WC ($r = 0.773$). A higher BMI-
305 protein signature (HR per SD increment = 1.80, 95% CI 1.72 to 1.89) and WC-protein
306 signature (HR = 1.97, 95% CI 1.87 to 2.07) at baseline were strongly associated with type 2
307 diabetes incidence over a median follow-up of 19.4 years.

308 **Pathway enrichment analysis**

309 In our pathway enrichment analysis, we identified 36 significant annotations from the BMI-
310 protein signature and 28 significant annotations from the WC-protein signature
311 (**Supplementary Table 9**). Pathways related to post-translational protein phosphorylation,
312 the regulation of insulin-like growth factor (IGF) transport and uptake by insulin-like growth
313 factor binding proteins (IGFBPs), and complement and coagulation cascades were
314 significantly enriched ($P_{FDR} < 0.05$) in both BMI- and WC-protein signatures. In addition,
315 pathways involved in adenosine monophosphate-activated protein kinase (AMPK) signaling,
316 extracellular matrix (ECM) receptor interaction, and cell adhesion molecules (CAMs)– were
317 significantly enriched ($P_{FDR} < 0.05$) in the WC-protein signature.

318 **Discussion**

319 We identified 410 proteins associated with BMI and 385 proteins associated with waist
320 circumference that were consistent across all three Asian ethnic groups (Chinese, Malay, and
321 Indian) in our study population. We derived protein signatures of BMI and WC which we
322 validated in an independent dataset across two timepoints and externally in a cohort of US
323 white and African American participants. Compared to anthropometric measurements, our
324 protein signatures were more strongly associated with cardiometabolic risk factors and were
325 able to distinguish between metabolically healthy and unhealthy obesity. In prospective

326 analyses, both protein signatures were strongly associated with the risk of type 2 diabetes in
327 MEC1 and the ARIC study. Biological pathways related to post-translational protein
328 phosphorylation, regulation of IGFs and IGFbps, coagulation cascades, AMPK signaling,
329 ECM receptor interaction, and cell adhesion were overrepresented in the BMI- and WC-
330 protein signatures.

331 Of the 410 proteins associated with BMI in our Asian cohort, over 80% of the proteins
332 measured in common were replicated in previous studies in European populations (4–6),
333 highlighting the robustness of these findings to ethnic and geographical variation. In addition,
334 we identified novel proteins that were not previously reported, most likely because of the
335 larger number of proteins represented in the proteomic assay used in our study. These include
336 serine protease high temperature requirement A1 (HTRA1), syndecan-3 (SDC3), and
337 complexin-2 (CPLX2). HTRA1 has been shown to regulate the availability of IGFs (31,32).
338 In addition, HTRA1 may inhibit adipogenesis by regulating the formation of adipocytes and
339 could be an indicator of adipose tissue dysfunction (33). Variants of the SDC3 gene have
340 been associated with obesity in Korean (34) and Taiwanese adults (35). SDC3 is involved in
341 regulating appetite through the melanocortin system (36) and may, therefore, be a potential
342 therapeutic target for treating obesity. CPLX2 may affect the translocation of glucose
343 transporter 4 (GLUT4), which plays a critical role in glucose uptake regulation (37).
344 However, it should be noted that GLUT4 translocation is an intracellular process, and
345 whether plasma levels of CPLX2 are related to this process is unclear. In addition, CPLX2
346 may also have a role in the regulation of the immune system (38). These novel adiposity-
347 related proteins, if replicated, can inform research on the pathophysiology of obesity and
348 related cardiometabolic conditions.

349 Using supervised machine learning techniques, we identified protein signatures of BMI and
350 WC and validated these across two timepoints in an independent dataset and externally in the

351 ARIC study. A large proportion (85%) of the proteins significantly associated with WC and
352 BMI in MEC1 overlapped. However, greater differences existed in proteins selected by
353 machine learning for the BMI and WC signatures, with slightly less than half of the proteins
354 overlapping. We further showed that the BMI-protein signature was highly correlated with
355 total body fat mass, whereas the WC-protein signature was more strongly correlated with
356 VAT. These findings suggest that the two protein signatures were able to capture the
357 differences in plasma proteins associated with adiposity in different anatomical
358 compartments.

359 Compared to anthropometric measures, the BMI- and WC-protein signatures were more
360 strongly associated with HDL-cholesterol, triglycerides, hemoglobin A1c levels, and the
361 incidence of type 2 diabetes. In addition, the associations of these protein signatures with
362 CVD risk factors and type 2 diabetes remained significant after further adjustment for BMI or
363 WC. These findings suggest that the protein signatures are likely to capture physiologically
364 relevant effects of body fat better than traditional measures of adiposity.

365 The identified plasma protein signatures differentiated between metabolically healthy and
366 metabolically unhealthy obesity and were associated with type 2 diabetes risk. Thus, the
367 biological pathways represented by the adiposity-related proteins may provide mechanistic
368 insights in the physiological changes associated with metabolically unhealthy obesity (39).
369 Pathways related to complement and coagulation cascades, IGFs and IGFBPs regulation, and
370 post-translational protein phosphorylation were significantly enriched in both the BMI-and
371 WC-protein signatures. In addition, pathways involving AMPK signaling, ECM-receptor
372 interaction, and CAMs were enriched in the WC-protein signature. The dysregulation of the
373 complement system resulting from overexpression of cytokines and adipose tissue-derived
374 factors may lead to chronic inflammation and the development of metabolic disorders such as
375 insulin resistance and type 2 diabetes (40). Similarly, imbalances in levels of IGFs and

376 IGFbps have been linked to the dysregulation of fat metabolism and insulin resistance (41–
377 43). AMPK is a key enzyme involved in regulating energy and nutrient metabolism, and the
378 dysregulation of AMPK has been implicated in the development of obesity, insulin
379 resistance, and type 2 diabetes (44). The over-activation of ECM receptor signaling pathways
380 may lead to inflammation and insulin resistance (45). Elevation of CAMs has been previously
381 associated with obesity and type 2 diabetes (46,47) and may affect inflammation and
382 atherogenesis (48). Taken together, the pathways enriched in the adiposity-related protein
383 signatures depict a state of dysregulated cell signaling, systemic inflammation, and impaired
384 glucose and fat metabolism. In addition, several of the pathways (e.g., complement pathways,
385 ECM-receptor interaction, and IGFBP regulation) enriched in our adiposity-related protein
386 signatures were also enriched in type 2 diabetes-associated proteins in European populations
387 (49), underscoring the central role of obesity-related pathways in the pathogenesis of type 2
388 diabetes.

389 Previous studies have reported ethnic differences in the association between obesity and
390 insulin resistance (29,50). Khoo et al. (29) demonstrated that the association of body fat
391 percentage with insulin resistance was weaker in ethnic Indians than in Chinese and Malays
392 residing in Singapore. Furthermore, Retnakaran et al. (50) found that pre-pregnancy BMI was
393 more strongly associated with insulin resistance in East Asian women than in South Asian
394 women in Canada. Here, while associations between plasma proteins and adiposity measures
395 were consistent across ethnic groups, we observed stronger associations between the BMI-
396 and WC-protein signatures and type 2 diabetes risk in Chinese and Malays than Indians.
397 These findings suggest that ethnic differences in the associations between obesity and type 2
398 diabetes may be explained by differential effects of obesity-related proteins on type 2
399 diabetes.

400 We acknowledge the limitations of our study. First, the plasma proteome including both
401 secreted and leakage proteins has been shown to be informative about the current and future
402 state of health (15,19), but the concentration of leakage proteins in the plasma may not be a
403 direct reflection of its biological activity in the cells. Second, we were not able to infer
404 causality as the associations between plasma proteins and anthropometric measurements were
405 cross-sectional. Even though our participants did not have type 2 diabetes at baseline, early
406 manifestations of diabetes may have influenced plasma protein levels. Third, while studies
407 have demonstrated the specificity of the SomaScan assay (18,19), it remains possible that
408 some proteins may not be correctly identified by the SomaScan platform used in our study.

409 In conclusion, our findings on adiposity-related proteins were robust across ethnic and
410 geographically diverse groups and have potential uses for assessing and monitoring
411 metabolically adverse adiposity. While further studies are needed to evaluate the causal
412 relationship between the identified proteins and adiposity, the results from this study can lead
413 to a better understanding of the biological mechanisms relating obesity and type 2 diabetes
414 and why sub-groups of the population differ in their susceptibility to adverse effects of
415 obesity on metabolic health.

416

417 **Acknowledgments**

418 We thank all participants, the study team, and the investigators for their research
419 contributions. The MEC1 study is supported by individual research and clinical scientist
420 award schemes from the Singapore National Medical Research Council (NMRC, including
421 MOH-000271-00) and the Singapore Biomedical Research Council (BMRC), the Singapore
422 Ministry of Health (MOH), the National University of Singapore (NUS) and the Singapore
423 National University Health System (NUHS). The Atherosclerosis Risk in Communities study
424 has been funded in whole or in part with Federal funds from the National Heart, Lung, and
425 Blood Institute, National Institutes of Health, Department of Health and Human Services,
426 under Contract nos. (75N92022D00001, 75N92022D00002, 75N92022D00003,
427 75N92022D00004, 75N92022D00005). The funders had no role in the design,
428 implementation, analysis, and interpretation of the data.

429 **Author contributions**

430 X.S., and R.M.vD designed the study. C.G.Y.L., X.S., R.M.vD, B.O., M.R.R., C.E.N., J.C.,
431 J.Y., Y.L., E.S.T., N.E.E.K. contributed to the acquisition, analysis, or interpretation of data.
432 C.G.Y.L., X.S., R.M.vD. contributed to the drafting of manuscript. E.S.T., B.O., M.R.R.,
433 C.E.N., J.C. contributed to the critical revision of manuscript. X.S. is the guarantor of this
434 work and, as such, had full access to all the data in the study and takes responsibility for the
435 integrity of the data and the accuracy of the data analysis.

436 **Disclaimers:** The National University of Singapore has signed a collaboration agreement
437 with SomaLogic to conduct SomaScan of MEC stored samples at no charge in exchange for
438 the rights to analyze linked MEC phenotype data.

439 **Conflict of interest:** All authors report no conflict of interest.

440

441 **References**

- 442 1. Hruby A, Hu FB. The Epidemiology of Obesity: A Big Picture. *Pharmacoeconomics*.
443 2015 Dec 4;33(7):673–89.
- 444 2. Riaz H, Khan MS, Siddiqi TJ, Usman MS, Shah N, Goyal A, et al. Association
445 Between Obesity and Cardiovascular Outcomes: A Systematic Review and Meta-
446 analysis of Mendelian Randomization Studies. *JAMA Netw Open*. 2018 Nov
447 2;1(7):e183788–e183788.
- 448 3. Hanash S. Disease proteomics. *Nature*. 2003 Mar 13;422(6928):226–32.
- 449 4. Carayol J, Chabert C, Di Cara A, Armenise C, Lefebvre G, Langin D, et al. Protein
450 quantitative trait locus study in obesity during weight-loss identifies a leptin regulator.
451 *Nat Commun*. 2017 Dec 1;8(1).
- 452 5. Zaghlool SB, Sharma S, Molnar M, Matías-García PR, Elhadad MA, Waldenberger M,
453 et al. Revealing the role of the human blood plasma proteome in obesity using genetic
454 drivers. *Nat Commun*. 2021 Feb 24;12(1):1–13.
- 455 6. Goudswaard LJ, Bell JA, Hughes DA, Corbin LJ, Walter K, Davey Smith G, et al.
456 Effects of adiposity on the human plasma proteome: observational and Mendelian
457 randomisation estimates. *Int J Obes (Lond)*. 2021 Oct;45(10):2221–9.
- 458 7. Ma RCW, Chan JCN. Type 2 diabetes in East Asians: similarities and differences with
459 populations in Europe and the United States. *Ann N Y Acad Sci*. 2013;1281(1):64–91.
- 460 8. Tan KHX, Tan LWL, Sim X, Tai ES, Lee JJM, Chia KS, et al. Cohort Profile: The
461 Singapore Multi-Ethnic Cohort (MEC) study. *Int J Epidemiol*. 2018;47(3):699–699j.
- 462 9. Khaing NEE, Shyong TE, Lee J, Soekojoo CY, Ng A, Van Dam RM. Epicardial and
463 visceral adipose tissue in relation to subclinical atherosclerosis in a Chinese
464 population. *PLoS One*. 2018 Apr 1;13(4):e0196328.
- 465 10. Ng AC, Wai DC, Tai ES, Ng KM, Chan LL. Visceral adipose tissue, but not waist
466 circumference is a better measure of metabolic risk in Singaporean Chinese and Indian
467 men. *Nutr Diabetes*. 2012 Aug 6;2(8):e38–e38.
- 468 11. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards
469 of Medical Care in Diabetes—2021. *Diabetes Care*. 2021 Jan
470 1;44(Supplement_1):S15–33.
- 471 12. Steffen BT, Tang W, Lutsey PL, Demmer RT, Selvin E, Matsushita K, et al. Proteomic
472 analysis of diabetes genetic risk scores identifies complement C2 and neuropilin-2 as
473 predictors of type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) Study.
474 *Diabetologia*. 2022 Jan 1;66(1):105–15.
- 475 13. Rohloff JC, Gelinis AD, Jarvis TC, Ochsner UA, Schneider DJ, Gold L, et al. Nucleic
476 Acid Ligands With Protein-like Side Chains: Modified Aptamers and Their Use as
477 Diagnostic and Therapeutic Agents. *Mol Ther Nucleic Acids*. 2014;3(10):e201.
- 478 14. Gold L, Ayers D, Bertino J, Bock C, Bock A, Brody EN, et al. Aptamer-Based
479 Multiplexed Proteomic Technology for Biomarker Discovery. *PLoS One*.
480 2010;5(12):e15004.
- 481 15. Williams SA, Kivimaki M, Langenberg C, Hingorani AD, Casas JP, Bouchard C, et al.

- 482 Plasma protein patterns as comprehensive indicators of health. *Nat Med.* 2019 Dec
483 2;25(12):1851–7.
- 484 16. Kim CH, Tworoger SS, Stampfer MJ, Dillon ST, Gu X, Sawyer SJ, et al. Stability and
485 reproducibility of proteomic profiles measured with an aptamer-based platform. *Sci*
486 *Reports* 2018 81. 2018 May 30;8(1):1–10.
- 487 17. Tin A, Yu B, Ma J, Masushita K, Daya N, Hoogeveen RC, et al. Reproducibility and
488 Variability of Protein Analytes Measured Using a Multiplexed Modified Aptamer
489 Assay. *J Appl Lab Med.* 2019 Jul 1;4(1):30.
- 490 18. Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, et al. Genomic
491 atlas of the human plasma proteome. *Nature.* 2018 Jun 6;558(7708):73–9.
- 492 19. Emilsson V, Ilkov M, Lamb JR, Finkel N, Gudmundsson EF, Pitts R, et al. Co-
493 regulatory networks of human serum proteins link genetics to disease. *Science.* 2018
494 Aug 8;361(6404):769.
- 495 20. NCBI. LOC652493 ig kappa chain V-I region HK102-like [Homo sapiens (human)] -
496 Gene - NCBI [Internet]. 2011.
- 497 21. Zou H, Hastie T. Regularization and variable selection via the elastic net. *J R Stat Soc*
498 *Ser B (Statistical Methodol.* 2005 Apr 1;67(2):301–20.
- 499 22. Blüher M. Metabolically Healthy Obesity. *Endocr Rev.* 2020 Jun 1;41(3):405–20.
- 500 23. Bateman A, Martin MJ, Orchard S, Magrane M, Ahmad S, Alpi E, et al. UniProt: the
501 Universal Protein Knowledgebase in 2023. *Nucleic Acids Res.* 2023 Jan
502 6;51(D1):D523–31.
- 503 24. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene
504 Ontology: tool for the unification of biology. *Nat Genet.* 2000 May;25(1):25.
- 505 25. Kanehisa M, Goto S. KEGG: Kyoto Encyclopedia of Genes and Genomes. *Nucleic*
506 *Acids Res.* 2000 Jan 1;28(1):27–30.
- 507 26. Fabregat A, Jupe S, Matthews L, Sidiropoulos K, Gillespie M, Garapati P, et al. The
508 Reactome Pathway Knowledgebase. *Nucleic Acids Res.* 2018 Jan 1;46(Database
509 issue):D649.
- 510 27. Kolberg L, Raudvere U, Kuzmin I, Vilo J, Peterson H. gprofiler2 -- an R package for
511 gene list functional enrichment analysis and namespace conversion toolset g:Profiler.
512 *F1000Research.* 2020 Jul 15;9:709.
- 513 28. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and
514 Powerful Approach to Multiple Testing. *J R Stat Soc Ser B.* 1995 Jan 1;57(1):289–
515 300.
- 516 29. Khoo CM, Khee-Shing Leow M, Sadananthan SA, Lim R, Venkataraman K, Khoo
517 EYH, et al. Body Fat Partitioning Does Not Explain the Interethnic Variation in
518 Insulin Sensitivity Among Asian Ethnicity: The Singapore Adults Metabolism Study.
519 *Diabetes.* 2014 Mar 1;63(3):1093–102.
- 520 30. Khoo CM, Sairazi S, Taslim S, Gardner D, Wu Y, Lee J, et al. Ethnicity Modifies the
521 Relationships of Insulin Resistance, Inflammation, and Adiponectin With Obesity in a
522 Multiethnic Asian Population. *Diabetes Care.* 2011 May 1;34(5):1120–6.

- 523 31. Hou J, Clemmons DR, Smeekens S. Expression and characterization of a serine
524 protease that preferentially cleaves insulin-like growth factor binding protein-5. *J Cell*
525 *Biochem.* 2005 Feb 15;94(3):470–84.
- 526 32. Jacobo SMP, DeAngelis MM, Kim IK, Kazlauskas A. Age-Related Macular
527 Degeneration-Associated Silent Polymorphisms in HtrA1 Impair Its Ability To
528 Antagonize Insulin-Like Growth Factor 1. *Mol Cell Biol.* 2013 May 1;33(10):1976.
- 529 33. Tiaden AN, Bahrenberg G, Mirsaidi A, Glanz S, Blüher M, Richards PJ. Novel
530 Function of Serine Protease HTRA1 in Inhibiting Adipogenic Differentiation of
531 Human Mesenchymal Stem Cells via MAP Kinase-Mediated MMP Upregulation.
532 *Stem Cells.* 2016 Jun 1;34(6):1601–14.
- 533 34. Ha E, Kim MJ, Choi BK, Rho JJ, Oh DJ, Rho TH, et al. Positive Association of
534 Obesity with Single Nucleotide Polymorphisms of Syndecan 3 in the Korean
535 Population. *J Clin Endocrinol Metab.* 2006 Dec 1;91(12):5095–9.
- 536 35. Chang BCC, Hwang LC, Huang WH. Positive Association of Metabolic Syndrome
537 with a Single Nucleotide Polymorphism of Syndecan-3 (rs2282440) in the Taiwanese
538 Population. *Int J Endocrinol.* 2018;2018.
- 539 36. Reizes O, Benoit SC, Strader AD, Clegg DJ, Akunuru S, Seeley RJ. Syndecan-3
540 Modulates Food Intake by Interacting with the Melanocortin/AgRP Pathway. *Ann N Y*
541 *Acad Sci.* 2003 Jun 1;994(1):66–73.
- 542 37. Pavarotti MA, Tokarz V, Frendo-Cumbo S, Bilan PJ, Liu Z, Zanni-Ruiz E, et al.
543 Complexin-2 redistributes to the membrane of muscle cells in response to insulin and
544 contributes to GLUT4 translocation. *Biochem J.* 2021 Jan 29;478(2):407–22.
- 545 38. Tsuru E, Oryu K, Sawada K, Nishihara M, Tsuda M. Complexin 2 regulates secretion
546 of immunoglobulin in antibody-secreting cells. *Immunity, Inflamm Dis.* 2019 Dec
547 1;7(4):318–25.
- 548 39. Iacobini C, Pugliese G, Blasetti Fantauzzi C, Federici M, Menini S. Metabolically
549 healthy versus metabolically unhealthy obesity. *Metabolism.* 2019 Mar 1;92:51–60.
- 550 40. Shim K, Begum R, Yang C, Wang H. Complement activation in obesity, insulin
551 resistance, and type 2 diabetes mellitus. *World J Diabetes.* 2020 Jan 1;11(1):1.
- 552 41. Friedrich N, Thuesen B, Jørgensen T, Juul A, Spielhagen C, Wallaschofski H, et al.
553 The Association Between IGF-I and Insulin Resistance: A general population study in
554 Danish adults. *Diabetes Care.* 2012 Apr;35(4):768.
- 555 42. Haywood NJ, Slater TA, Matthews CJ, Wheatcroft SB. The insulin like growth factor
556 and binding protein family: Novel therapeutic targets in obesity & diabetes. *Mol*
557 *Metab.* 2019 Jan 1;19:86.
- 558 43. Clemmons DR. Role of IGF-binding proteins in regulating IGF responses to changes
559 in metabolism. *J Mol Endocrinol.* 2018 Jul 1;61(1):T139–69.
- 560 44. Steinberg GR, Hardie DG. New insights into activation and function of the AMPK.
561 *Nat Rev Mol Cell Biol.* 2023 Apr;24(4):255–72.
- 562 45. Lin D, Chun TH, Kang L. Adipose extracellular matrix remodelling in obesity and
563 insulin resistance. *Biochem Pharmacol.* 2016 Nov 1;119:8–16.

- 564 46. Hegazy GA, Awan Z, Hashem E, Al-Ama N, Abunaji AB. Levels of soluble cell
565 adhesion molecules in type 2 diabetes mellitus patients with macrovascular
566 complications. *J Int Med Res*. 2020;48(4):1–11.
- 567 47. Miller MA, Cappuccio FP. Cellular adhesion molecules and their relationship with
568 measures of obesity and metabolic syndrome in a multiethnic population. *Int J Obes*
569 2006 308. 2006 Mar 7;30(8):1176–82.
- 570 48. Hope SA, Meredith IT. Cellular adhesion molecules and cardiovascular disease. Part I.
571 Their expression and role in atherogenesis. *Intern Med J*. 2003 Aug 1;33(8):380–6.
- 572 49. Gudmundsdottir V, Zaghlool SB, Emilsson V, Aspelund T, Ilkov M, Gudmundsson
573 EF, et al. Circulating Protein Signatures and Causal Candidates for Type 2 Diabetes.
574 *Diabetes*. 2020 Aug 1;69(8):1843.
- 575 50. Retnakaran R, Hanley AJG, Connelly PW, Sermer M, Zinman B. Ethnicity Modifies
576 the Effect of Obesity on Insulin Resistance in Pregnancy: A Comparison of Asian,
577 South Asian, and Caucasian Women. *J Clin Endocrinol Metab*. 2006 Jan 1;91(1):93–7.
- 578
- 579

580 **Tables**

581 **Table 1.** Pearson correlation coefficients between body mass index (BMI) and waist circumference
 582 (WC) protein signatures and anthropometric, DXA, and CT adiposity measurements in the T2DCC
 583 Set.

	BMI signature			WC signature		
	Cases	Controls	Combined	Cases	Controls	Combined
<u>Anthropometric measurements at baseline *</u>						
BMI, kg/m ²	0.815	0.847	0.842	0.675	0.731	0.726
WC, cm	0.639	0.717	0.716	0.675	0.798	0.778
<u>Anthropometric measurements at follow-up †</u>						
BMI, kg/m ²	0.809	0.829	0.823	0.696	0.712	0.713
WC, cm	0.712	0.742	0.752	0.726	0.791	0.783
<u>DXA measurements ‡</u>						
Total body fat mass, kg	0.756	0.789	0.782	0.628	0.583	0.619
Lean mass, %	-0.482	-0.484	-0.488	-0.270	-0.171	-0.232
Android fat mass, kg	0.755	0.787	0.787	0.706	0.689	0.717
Trunk fat mass, kg	0.764	0.812	0.801	0.685	0.665	0.691
<u>CT measurements §</u>						
SAT volume, cm ²	0.499	0.641	0.596	0.418	0.378	0.433
VAT volume, cm ²	0.542	0.719	0.676	0.603	0.776	0.735

584 All correlation coefficients were statistically significant at P <0.001. Abbreviations: BMI, body mass
 585 index; Computed Tomography, CT; DXA, Dual-Energy X-ray Absorptiometry; SAT, subcutaneous
 586 adipose tissue; T2DCC, type 2 diabetes case control; VAT, visceral adipose tissue; WC, waist
 587 circumference.

588 * Measured among all participants in the T2DCC Set at baseline; n = 616 for cases, 1,200 for controls,
 589 and 1,816 when combined.

590 † Measured among all participants in the T2DCC Set at follow-up; n = 327 for cases, 487 for controls,
 591 and 814 when combined.

592 ‡ Measured in a subset of Chinese participants at follow-up; n = 69 for cases, 138 for controls, and
 593 207 when combined.

594 § Measured in a subset of Chinese participants at follow-up; n = 51 for cases, 100 for controls, and
 595 151 when combined.

596

597 **Table 2.** Associations between anthropometric measurements, protein signatures of adiposity, and the
598 incidence of type 2 diabetes.

	OR (95% CI)	P-value	P_{diff} *
BMI	1.91 (1.70, 2.14)	1.95E-28	
BMI-protein signature	2.44 (2.15, 2.77)	1.19E-42	0.005
BMI-protein signature adjusted for BMI	2.69 (2.18, 3.32)	3.80E-20	
WC	2.09 (1.86, 2.36)	2.09E-33	
WC-protein signature	2.84 (2.47, 3.25)	1.64E-50	0.001
WC-protein signature adjusted for WC	2.69 (2.23, 3.25)	6.25E-25	


599 All predictor variables were expressed as per 1 SD increment to facilitate the comparison of effect
600 sizes. All models were adjusted for age, sex, and ethnicity.

601 Abbreviations: BMI, body mass index; WC, waist circumference.

602 * P-value for difference between the standardized coefficients for BMI and the BMI-protein signature,
603 and the coefficients between WC and the WC-protein signature, calculated using the Z test.

604

605 **Figures**



606 **Figure 1.** Overview of the study design.* Measured in a subset of Chinese participants in the MEC1
607 (n = 207) at follow-up. † Measured in a subset of Chinese participants in the MEC1 (n = 151) at
608 follow-up. ‡ Cross-sectional correlations between protein signatures and anthropometric
609 measurements at baseline (n = 1,816) and follow-up (n = 814). Longitudinal correlations between the
610 change in protein signatures and change in anthropometric measurements in participants with data
611 across two timepoints (n = 814). Abbreviations: ARIC, Atherosclerosis Risk in Communities; BMI,
612 body mass index; CT, computed tomography; CVD, cardiovascular disease; DXA, dual-energy X-ray
613 absorptiometry; MEC1, Multi-Ethnic Cohort Phase 1; T2DCC, T2D case-control; WC, waist
614 circumference.
615


616

617

618

619

620



621

622 **Figure 2.** (a) Volcano-plot of $-\log_{10}(P_{\text{BMI}})$ against $\log_2(\text{fold change})$ per kg/m^2 increment of BMI. (b)

623 Volcano-plot of $-\log_{10}(P_{\text{WC}})$ against $\log_2(\text{fold change})$ per cm increment of WC. Dashed lines

624 represent the threshold for statistical significance after Bonferroni correction. (c) Scatterplot of the

625 beta coefficients for WC against the beta coefficients for BMI. Text annotations are Entrez Gene

626 symbols and the full protein names are provided in Supplementary Table 4. (d) Venn diagram of the

627 number of proteins that were significantly associated with BMI and WC at the Bonferroni threshold.


628 Abbreviations: BMI, body mass index; WC, waist circumference.

629

630

631

645




646

647 **Figure 4.** Scatterplots of (a) total body fat mass against BMI-protein signature in 207 Chinese
648 participants with DXA and (b) visceral adipose tissue volume against the WC-protein signature in 151
649 Chinese participants with CT. Linear regression was fitted with the shaded region representing the
650 95% confidence intervals and the dotted lines representing the 95% prediction intervals.
651 Abbreviations: CT, computed tomography; DXA, dual-energy X-ray absorptiometry; SD, standard
652 deviation.

653

654 **Supplementary Figures**




655

656 **Supplementary Figure 1.** Scatterplots of (a) BMI against BMI-protein signature at baseline (b) WC
657 against WC-protein signature at baseline, (c) BMI against BMI-protein signature at follow-up, and (d)
658 WC against WC-protein signature at follow-up in the T2DCC Set. The diagonal lines represent the y
659 $= x$ line. Abbreviations: BMI, body mass index; T2DCC, type 2 diabetes case control; WC, waist
660 circumference.


661

662



663
664 **Supplementary Figure 2.** Scatterplots of (a) change in BMI against change in BMI-protein signature,
665 and (b) change in WC against change in WC-protein signature over a ~6-year period in the T2DCC
666 set. The diagonal lines represent the $y = x$ line. Abbreviations: BMI, body mass index; SD, standard
667 deviation; T2DCC, type 2 diabetes case control; WC, waist circumference.

668



669

670 **Supplementary Figure 3.** Comparison of the beta coefficients for the associations between plasma
671 proteins and BMI/WC between the Singapore Multi-ethnic cohort Phase 1 (MEC1) and the
672 Atherosclerosis Risk in Communities (ARIC) study for (a) the BMI-protein signature and (b) the WC-
673 protein signature. Plasma protein levels in relative fluorescence units (RFU) were quantified using the
674 SomaScan V4 assay in both studies. Each point corresponds to each protein in the respective protein
675 signatures ($n = 124$ for the BMI-protein signature and $n = 125$ for the WC-protein signature).
676 Abbreviations: BMI, body mass index; WC, waist circumference.